EVUSHIELD CHECKLIST FOR MFA PROVIDERS

Tixagevimab plus cilgavimab (Evusheld), administered as intramuscular injections as SARS-CoV-2 pre-exposure prophylaxis (PrEP), can be ordered in Epic and administered as a pair of intramuscular injections in your designated clinical areas. Below are the recommended steps to follow.

PATIENT SELECTION AND ORDERING

☐ Review the “GW-MFA Guidance on Monoclonal Antibody Evusheld for Pre-Exposure Prophylaxis of COVID-19” document which highlights the institutional recommendations for appropriate Evusheld use and patient eligibility.

☐ Given the limited supply of Evusheld and the narrow criteria for its use, each MFA Department/Division is asked to designate up to two providers as Evusheld prescribers to ensure adherence to institutional recommendations.

☐ After patient selection, prescribers must place an order in Epic for Evusheld as a clinic administered medication.
  • If a patient has not received Evusheld, order the 600 mg dose (tixagevimab 300 mg/3.0 mL and cilgavimab 300 mg/3.0 mL).
  • If a patient received Evusheld at the previously authorized 300 mg dose (tixagevimab 150 mg/1.5 mL and cilgavimab 150 mg/1.5 mL), order a repeat 300 mg dose (tixagevimab 150 mg/1.5 mL and cilgavimab 150 mg/1.5 mL).

☐ Your designated clinic/nurse manager must request the corresponding number of Evusheld packs via Cognito here (must use Google Chrome) and then pick up from the clinic pharmacy dispensary.

☐ At the time of pick up, staff should provide the medical record number (MRN) of the patient(s) to receive administration to ensure equity and accountability in allocation.

ADMINISTRATION

☐ Patients can receive Evusheld during a scheduled clinic visit or as a walk-in injection visit.

☐ Before administration, provide a copy of the Evusheld Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization. This is not an informed consent (does not need a signature).

☐ The patient should receive the two components of Evusheld consecutively.
  • Currently authorized dose (3 mL per injection): the gluteal muscles are preferred.
  • Previously authorized dose (1.5 mL per injection): the deltoid or gluteal muscles can be used.

☐ Individuals should be monitored clinically after injections for 1 hour.